Sign in Register

Sulfamylon (mafenide acetate)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Mafenide is a synthetic anti-infective agent that is closely related chemically, but not pharmacologically, to the sulfonamides.

Mafenide acetate cream is used as an adjunct in the treatment of second- and third-degree burns to prevent septicemia caused by susceptible organisms, especially Pseudomonas aeruginosa. Treatment with mafenide acetate cream should begin after measures to control shock and pain have been instituted. Mafenide acetate cream has been shown to markedly reduce the incidence of sepsis in patients with second- and third-degree burns resulting in a decrease in the mortality rate of patients with burns covering 60% or less of the body surface.

Reduction in bacterial growth also may prevent conversion of partial thickness wounds to full thickness.

Generic name: mafenide acetate
Pronunciation: (MAF-en-ide AS-e-tate)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Sulfamylon

Intelligence content is not available yet.

Indications

The following indications are listed for Sulfamylon:

  • Infection Of Burn Wound

Also known as: Burn Wound Infection, Infected Burn Wound.

Dosing

Mafenide acetate cream is applied topically. The potency of mafenide acetate cream is expressed in terms of mafenide. Each g of mafenide acetate cream provides the equivalent of 85 mg of mafenide. Dosage and administration recommendations are the same for both adults and pediatric patients.

Mafenide acetate cream may be applied to the cleansed, debrided burned areas once or twice daily with a sterile-gloved hand. The cream should be applied to a thickness of approximately 16 mm (one-sixteenth inch); thicker application is not recommended. The burned area should be covered with cream at all times. Whenever necessary, the cream should be reapplied to any areas from which it has been removed (e.g., by patient activity). If possible, the patient should be bathed daily, preferably in a whirlpool bath, to aid in debridement. Dressings are generally not required; if they are necessary, only a thin layer of dressing should be used. Dressings have been applied by some clinicians when the eschar begins to separate (16-20 days) in order to expedite the separation of the eschar.

Therapy with mafenide acetate cream is usually continued until healing is progressing well or until the site is ready for grafting. Mafenide acetate topical therapy should generally not be withdrawn from the therapeutic regimen while there is the possibility of infection; however, if allergic manifestations occur, discontinuance of mafenide acetate should be considered. If systemic acidosis occurs and is difficult to control, especially in patients with pulmonary dysfunction, discontinuing mafenide acetate therapy for 24-48 hours while continuing fluid therapy may aid in restoring acid-base balance.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data